ReviewFrontiers in cellular and infection microbiology2024
Gut microbiota and psoriasis: pathogenesis, targeted therapy, and future directions.
Review in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping the global research landscape on psoriasis and the gut microbiota: visualization and bibliometric analysis.Frontiers in cellular and infection microbiology · 2025Pooled it
- Probiotics in Autoimmune Disease: Strain-specific Mechanisms and Therapeutic Perspectives.Clinical reviews in allergy & immunology · 2026Review
- Dietary Adjuvanticity in the Modern Plant Exposome: Implications for Immune-Mediated Inflammatory Diseases.Nutrients · 2026Review
- Prevotella copri Exacerbates Psoriasis Through Keratinocyte-Neutrophil Crosstalk via NF-κB Activation.Experimental dermatology · 2026Article
- Dietary Polysaccharides in Skin Health: Structure-Function Relationships and Implications for Nutritional Dermatology.Nutrients · 2026Review
- Immunoprotective and neuroprotective properties of gut microbiome in psoriasis.Journal of translational autoimmunity · 2026Review
- Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives.Nutrients · 2026Review
- Pharmacomicrobiomics in Psoriasis: Microbiome-Drug Interactions Across Systemic Treatments.Life (Basel, Switzerland) · 2026Review
- Psoriasis beyond the skin: systemic inflammation as a bridge to metabolic and hepatic comorbidities.Inflammopharmacology · 2026Review
- Evaluation of Major Autohemotherapy (MAH) in Psoriasis Patients Using Serum Inflammatory Markers.Journal of clinical medicine · 2026Article
- The brain-gut-skin axis in inflammatory and disfiguring skin diseases: mechanistic insights, clinical correlations, and therapeutic strategies.Frontiers in immunology · 2026Review
- Microbiome and Skin Health: A Systematic Review of Nutraceutical Interventions, Disease Severity, Inflammation, and Gut Microbiota.Microorganisms · 2025Review
- Topical Probiotics as a Novel Approach in the Treatment of Chronic Dermatoses Associated with Skin Dysbiosis: A Narrative Review.International journal of molecular sciences · 2025Review
- Gut-skin axis: Emerging insights for gastroenterologists-a narrative review.World journal of gastrointestinal pathophysiology · 2025Review
- Dietary Principles, Interventions and Oxidative Stress in Psoriasis Management: Current and Future Perspectives.Medicina (Kaunas, Lithuania) · 2025Review
- Targeting psoriatic inflammation with natural compounds: mechanistic insights and therapeutic promise.Inflammopharmacology · 2025Review
- Review
- Review
- Psoriasis and gut microbes: research advances from mechanism to therapy.Frontiers in microbiology · 2025Review
- Clinical Treatment and Clinical Application Research Progress of Psoriasis and Intestinal Microbiota Dysbiosis.Clinical, cosmetic and investigational dermatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is one of the most common autoimmune skin diseases. Increasing evidence shows that alterations in the diversity and function of microbiota can participate in the pathogenesis of psoriasis through various pathways and mechanisms. Objective: To review the connection between microbial changes and psoriasis, how microbial-targeted therapy can be used to treat psoriasis, as well as the potential of prebiotics, probiotics, synbiotics, fecal microbiota transplantation, diet, and Traditional Chinese Medicine as supplementary and adjunctive therapies. Methods: Literature related to the relationship between psoriasis and gut microbiota was searched in PubMed and CNKI. Results: Adjunct therapies such as dietary interventions, traditional Chinese medicine, and probiotics can enhance gut microbiota abundance and diversity in patients with psoriasis. These therapies stimulate immune mediators including IL-23, IL-17, IL-22, and modulate gamma interferon (IFN-γ) along with the NF-kB pathway, thereby suppressing the release of pro-inflammatory cytokines and ameliorating systemic inflammatory conditions. Conclusion: This article discusses the direction of future research and clinical treatment of psoriasis from the perspective of intestinal microbiota and the mechanism of traditional Chinese medicine, so as to provide clinicians with more comprehensive diagnosis and treatment options and bring greater hope to patients with psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.